American Aires Inc. Appoints Corporate Secretary
Toronto, Ontario–(Newsfile Corp. – March 14, 2023) – American Aires Inc. (CSE: WIFI) (OTC Pink:…
Toronto, Ontario–(Newsfile Corp. – March 14, 2023) – American Aires Inc. (CSE: WIFI) (OTC Pink:…
LONDON AND HONG KONG, Mar 14, 2023 – (ACN Newswire) – Prenetics Global Limited (NASDAQ:…
NEW YORK, Mar 14, 2023 – NFT-TiX, the rapidly expanding ticketing and NFT Ticketing marketplace,…
Craft brand expands leadership team with alcohol beverage veterans LEXINGTON, Ky.–(BUSINESS WIRE)–Lexington-based RD1 Spirits announces…
Securiti closes out a strong year of customer adoption, partner growth and geographic expansion amid…
As legal holds and data management complexities rise, Sightline offers end-to-end modern discovery, investigations, and…
Armorblox has been recognized in the Gartner Market Guide for Email Security for the third…
Award-winning sneaker designer creates revolutionary, new platform to empower athletes, designers, influencers, and startups to…
Leading Diagnostic Healthcare Company Announces Provisional Patent Filing on Proprietary Use of Materials for Ophthalmological…
Professor Kranzler is the Benjamin Rush Professor of Psychiatry and Director of the Center for…
All proposals of the Board of Directors approved Severin Schwan elected as new Chairman of…
Presentation with live webcast today, March 14th at 10:40 AM ET DURHAM, N.C., March 14,…
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage…
MODIIN, Israel and NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT)…
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq:…
Greater China region, Israel, and Greece, Cyprus and Malta are now also covered by the…
Virtual Webinar to be held March 23, 2023, at 10:00am Eastern Time CARSON CITY, Nev.,…
-Pilot study in Ewing’s Sarcoma supports the therapeutic potential of Vigil in multiple solid tumor…
Media Release Integrated Phase II/III trial design incorporates feedback from the FDA and EMA and…
Initiation of APEX Part 2 planned for mid-2023 Updated clinical data from Phase 3 PEAK…